The Conversation (0)
April 04, 2022
Reem Capital Corp. (TSXV: REEM) ("REEM") is pleased to announce details concerning a proposed arm's length business combination (the "Transaction") with Kalron Holdings Ltd. ("Kalron"), a corporation formed under the laws of Israel.
Overview of Reem
Reem is a "capital pool company" under the policies of the TSX Venture Exchange (the "Exchange") and it is intended that the Transaction will constitute the "Qualifying Transaction" of Reem, as such term is defined in Exchange Policy 2.4 - Capital Pool Companies. The common shares of Reem (the "Reem Common Shares") are currently listed on the Exchange and Reem is a reporting issuer in the provinces of British Columbia, Alberta, and Ontario. Reem was incorporated under the Business Corporations Act (British Columbia) (the "BCBCA") on March 29, 2021.
Overview of Kalron Holdings Ltd ("Kalron") and Seegnal eHealth Ltd ("Seegnal")
Kalron is a privately-held holding corporation that was established under the laws of Israel in 2017. Kalron is the sole shareholder of Seegnal, an Israeli based corporation which had operated under Teva Pharmaceuticals Industries Ltd. ("Teva") until its purchase by Kalron in December 2017. Seegnal provides patient-tailored software as a service (SAAS) system for one-glance managing & mitigating drug related problems while providing decision support to healthcare professionals at the point of care. Seegnal has developed, owns and is marketing a concept of addressing the need of detecting and solving drug-related problems, which has been determined as the fourth leading cause of mortality in developed countries.1 Seegnal's SAAS based software platform is a patient-tailored, clinicians'-friendly drug-related problem solution. Seegnal exclusively integrates at the point-of-care, unique patients'-specific data like genetics, food, results of lab tests, ECG, smoking and the effects of many concomitant medications, while delivering accuracy, sensitivity and specificity.
Seegnal is currently selling its SAAS-based platform in the State of Israel and in the UAE. To date, Seegnal has also signed distribution agreements with several major entities in the US which are well established key-players in the field, and is preparing to launch the product in US hospitals in 2022, through its US wholly-owned subsidiary - Seegnal US Inc. Seegnal was founded by its CEO, Dr. Roni Shiloh, as a wholly-owned subsidiary of Teva in 2015. Dr. Shiloh, MD (with a strong background in Psychiatry) is the author of more than 40 manuscripts and textbooks on polypharmacy and drug interactions. Kalron was established by Dr. Shiloh and a large Israeli family office, and they jointly executed a management buyout of Seegnal from Teva in late December 2017.
Summary of the Proposed Transaction
Reem has entered into a non-binding letter of intent with Kalron dated April 1, 2022 (the "LOI") pursuant to which Reem and Kalron intend to complete the Transaction, and whereby Reem as it exists upon completion of the Transaction (the "Resulting Issuer") will continue the business of Kalron.
It is currently anticipated that the Transaction will occur as a merger, amalgamation or share exchange, the final structure of the Transaction being subject to receipt of tax, corporate and securities law advice for both Reem and Kalron. The LOI is expected to be superseded by a definitive agreement (the "Definitive Agreement") to be signed between the parties.
It is anticipated that each ordinary share of Kalron ("Kalron Shares") outstanding at the time of closing the Transaction ("Closing") (including the Kalron Shares issuable upon conversion of the Subscription Receipts (as defined below)) will be exchanged for an appropriately corresponding number of Reem Common Shares, with reference to the Offering Price (as defined below). Kalron will not receive any additional consideration for its shares. Prior to the Closing, it is intended that Reem shall consolidate the Reem Common Shares on such basis as is necessary to result in the deemed value of the Reem Common Shares being equal to $2,000,000. It is intended that the Reem Common Shares will be issued to holders of the Kalron Shares on the basis of one Reem Common Share for every one Kalron Share. Each outstanding option and warrant to purchase Reem Common Shares shall be adjusted so that the number of shares issuable on exercise, and the exercise price thereof, are adjusted to give effect to such consolidation.
Reem shareholder approval is not required with respect to the Transaction under the rules of the Exchange because the Transaction does not constitute a "Non-Arm's Length Qualifying Transaction" pursuant to the policies of the Exchange. However, the structure of the Transaction is being finalized and, based on the final structure as reflected in the Definitive Agreement, shareholder approval may be required under applicable law. Trading in the Reem Common Shares has been halted and is not expected to resume until the Transaction is completed or until the Exchange receives the requisite documentation to resume trading.
It is expected that upon completion of the Transaction, the Resulting Issuer, to be renamed "Seegnal eHealth Ltd.", will be listed as a Tier 2 Technology Issuer on the Exchange.
A more comprehensive news release will be issued by Reem in due course disclosing details of the Transaction, including financial information respecting Kalron, the names and backgrounds of all persons who will constitute insiders of the Resulting Issuer, the issued and outstanding securities of each of Reem and Kalron, the terms of the exchange of securities of Reem and Kalron, the applicable security exchange ratios, the details of any meetings of the shareholders of Reem and Kalron, required to approve the Transaction and matters related thereto (as applicable), and information respecting sponsorship, once a Definitive Agreement has been executed and certain conditions have been met, including satisfactory completion of due diligence.
Concurrent Financing
In conjunction with, or prior to the Closing, it is expected that Kalron will complete a brokered private placement of subscription receipts of Kalron ("Subscription Receipts") to raise gross proceeds of at least $3,000,000 (the "Private Placement") at a price acceptable to Kalron in its sole discretion (the "Offering Price"). Each Subscription Receipt will be automatically exchanged immediately prior to the completion of the Transaction (without any further action by the holder of such Subscription Receipt and for no further payment) for one Kalron Share upon satisfaction of certain escrow release conditions.
Forward Looking Information
This press release contains statements that constitute "forward-looking information" ("forward-looking information") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "believe", "estimate", "expect", "intend", "projected" or variations of such words and phrases or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.
More particularly and without limitation, this press release contains forward-looking statements concerning the Transaction (including the terms and timing thereof), the continued business of the Resulting Issuer, the issuance of additional news releases describing the Transaction, the name of the Resulting Issuer, the trading of the Reem Common Shares on the Exchange, the listing of the Resulting Issuer on the Exchange, and the holding of shareholder meetings in connection with the Transaction, launch of products by Seegnal in US hospitals in 2022 and the expansion of the Seegnal business. In disclosing the forward-looking information contained in this press release, Reem has made certain assumptions, including that: all applicable shareholder and regulatory approvals for the Transaction will be received; that the Transaction will be completed on mutually acceptable terms and within a customary timeframe for transactions of this nature and the acceptance of the Seegnal products by customers in the United States. Although Reem believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties and other factors may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: availability of financing; delay or failure to receive board, shareholder or regulatory approvals; and general business, economic, competitive, political and social uncertainties. There can be no certainty that the Transaction will be completed on the terms set out in the LOI or at all. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, Reem disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.
Completion of the Transaction is subject to a number of conditions, including but not limited to, execution of a binding definitive agreement relating to the Transaction, Exchange acceptance and, if applicable pursuant to Exchange requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.
Reem Capital Corp.
For further information, please contact:
Arthur H. Kwan, Chief Executive Officer
Reem Capital Corp.
Email: arthur_h_kwan@hotmail.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Neither the TSX Venture Exchange, Inc. nor its Regulation Services Provider (as that term is defined in the polices of the TSX Venture Exchange) has in any way passed upon the merits of the Transaction and associated transactions and neither of the foregoing entities has in any way approved or disapproved of the contents of this press release.
The securities have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA
REEM.P:CA
09 September
How to Invest in Medical Device Stocks and ETFs
The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.
This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and prevention of diseases and physical conditions, and it continues to develop rapidly.
Examples of medical devices include neurostimulation devices, surgical implants, ultrasound imaging devices and robotic medical technology, along with insulin pumps and insulin pens for diabetes. Just as pharmaceutical companies seek to serve unmet needs, medical device companies do the same via innovative technologies.
Here's a breakdown of how to invest in medical devices and what’s in store for the sector.
In this article
What should investors know about the medical device market?
Before investing in medical device stocks, it helps to understand their goals. Medtech companies will often seek to show investors that their products are ready to enter the market and will be in demand right away — whether it be by serving a large demographic or by targeting a specific ailment in the population that has an unmet medical need.
Like firms pursuing drug approvals, medical device companies must conduct clinical trials to bring their products to market; they have to refine their technology and confirm efficacy and safety to get regulatory approvals.
Successfully completed clinical trials and product approvals are usually major catalysts for a company’s share price. A medical device stock can experience a large jump when announcing positive results from a recent trial or approval from a regulatory body such as Health Canada, the US Food and Drug Administration (FDA) or an equivalent agency in Europe or Asia. On the other hand, poor results can have a negative impact on the company's performance.
Patentability also plays a big role in a medical device company’s value. Once a product has been patented, the company controls its every move and can choose to license it or make other deals to expand device reach.
What is the outlook for the medical device market?
The medical device and in-vitro diagnostics market is expected to experience growth in global annual sales of 5.2 percent each year from 2023 to reach nearly US$758.9 billion by 2030, according to a 2024 forecast from KPMG focused on technological advances and AI in the healthcare industry.
"Rapid innovation in diabetic care, cardiology, robotic surgery, internet-connected wearables, and a whole host of Al-enabled devices is causing a great deal of excitement among not only providers and patients, but also investors," the firm states.
Significant drivers of the sector's growth include increased demand for wearables and services like health data. "Enabled by sensor technology, computing power, increased bandwidth and Al, devices are changing care delivery for wellness, chronic condition management, diagnostics, and surgical procedures," KPMG wrote.
AI advancements in healthcare were also the focus of multiple panels at the 2025 Web Summit Vancouver conference, with many experts sharing their insights on the possibilities and challenges of using AI in healthcare.
Another demand driver is increasing prevalence of diseases, particularly cancer and diabetes, plus cardiovascular, neurological, orthopedic and respiratory diseases, which are on the rise due to an aging population.
The United Nations has said that by the end of 2050, the ratio of deaths per year due to chronic diseases is expected to rise to around 86 percent of total deaths each year.
KPMG also highlighted the role that the sector can play in addressing health inequities with devices that help rural and underserved communities access basic healthcare. This also requires digital equity for these communities, and the firm believes both goals should be worked towards at the same time.
How to invest in medical device stocks
Large-cap medical device stocks
The sector is dominated by a handful of big medical device manufacturers, which means investors interested in large-cap companies will have no trouble finding what they’re looking for. Here are a few to get you started:
Abbott Laboratories (NYSE:ABT)
Abbott Laboratories creates a wide range of products, from diagnostics to medical devices to branded generic pharmaceuticals. Its medical devices focus on segments including vascular diseases, diabetes and optometry.
Intuitive Surgical (NASDAQ:ISRG)
Medical device manufacturer Intuitive Surgical developed the da Vinci surgical system, the first minimally invasive surgical system to receive clearance from the US FDA. The company’s goal is to provide assistance to doctors and hospitals with its robotics-assisted platforms, including the da Vinci system.
Medtronic (NYSE:MDT)
Medtronic’s devices provide solutions for relieving pain, restoring health and working to extend the lives of millions of people globally. Its primary areas of focus include cardiac and vascular care, minimally invasive therapies, restorative therapies and diabetes.
Danaher (NYSE:DHR)
Globally diversified conglomerate Danaher has a number of brands under its corporate umbrella grouped in three distinct divisions: healthcare, diagnostics and environmental and applied end markets. Through its brands, Danaher designs, manufactures and sells a number of medical device products and services.
Thermo Fisher Scientific (NYSE:TMO)
Thermo Fisher Scientific's family of global products and services represents a broad range of high-end analytical instruments, chemistry and consumable supplies, laboratory equipment and software. It has products in a variety of areas, including cellular analysis, synthetic biology and molecular biology.
Small-cap medical device stocks
Investors will also find smaller-cap medical device companies amid the heavyweights — it’s just a matter of risk tolerance. Below are five great examples.
AngioDynamics (NASDAQ:ANGO)
AngioDynamics is a global medical technology company that designs, manufacturers and sells high-quality, minimally invasive medical devices. Its devices target vascular access procedures and treatment of peripheral vascular and oncological diseases.
Aurora Spine (TSXV:ASG,OTCQB:ASAPF)
Aurora Spine is a Canadian medical device company focused on the spinal implant market. It has a portfolio of minimally invasive, regenerative spinal implant technologies designed to improve spinal surgery outcomes. Its FDA-approved products include the DEXA patient-matched implant technology and the ZIP series of implants for lumbar spinal stenosis.
Delcath Systems (NASDAQ:DCTH)
Delcath Systems is a pharmaceutical and medical device company focused on “interventional oncology,” specifically regarding the treatment of primary and metastatic liver cancers. The company's commercial products combine its Hepactic Delivery System with the chemotherapeutic drug melphalan for to help liver cancer patients undergo safer high-dose chemotherapy.
Senseonics (NYSEAMERICAN:SENS)
Senseonics is a commercial-stage medical technology company that develops and manufactures continuous glucose monitoring systems for people with diabetes. The company’s Eversense 365 and Eversense E3 systems are long-term, implantable devices that use sensor technology to transmit frequent glucose data updates via a smartphone app.
iRhythm Technologies (NASDAQ:IRTC)
iRhythm Technologies’ wearable biosensor device, the Zio ECG monitor, is used for the diagnosis of cardiac arrhythmias. The FDA-cleared device uses AI and a clinically proven deep-learned algorithm to enable accurate diagnoses.
How to invest in medical device ETFs
For those who prefer to mitigate risk, exchange-traded funds (ETFs) are a safer way to put money into the market, and there are two primary medical device ETFs for investors to choose from.
ETFs hold assets such as stocks, commodities and bonds, and trade close to their net asset value. With exposure to various companies, any potential decrease in one stock won’t significantly drive down overall ETF returns.
Typically ETFs track an index. In the medical device arena, there are two indexes that can be followed: the S&P Health Care Equipment Select Industry Index (INDEXSP:SPSIHE) and the Dow Jones US Select Medical Equipment Index (INDEXDJX:DJSMDQ). Below are the two biggest medical device ETFs:
iShares US Medical Devices ETF (ARCA:IHI)
The iShares US Medical Device ETF is the largest ETF in the medical device sector. Its focus is on US companies that manufacture and distribute medical devices. This passive ETF tracks the Dow Jones US Select Medical Equipment Index. Three of its top holdings are Abbott Laboratories, Intuitive Surgical and Boston Scientific (NYSE:BSX).
SPDR S&P Health Care Equipment ETF (ARCA:XHE)
The SPDR S&P Health Care Equipment ETF tracks the S&P Health Care Equipment Select Industry Index. Its top holdings include Staar Surgical (NASDAQ:STAA), ResMed (NYSE:RMD) and iRhythm Technologies.
This is an updated version of an article originally published by the Investing News Network in 2017.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Keep reading...Show less
13 March
BlinkLab Completes First Patient Test for US Autism Diagnostic Study
Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.
BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.
The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.
"Launching our US trial marks a very special and important moment for BlinkLab. Our mission has always been to connect fundamental neuroscience with clinical practice through accessible technology, thereby enhancing autism diagnostic evaluations and enabling early intervention for children,” said CEO and Co-founder Dr. Henk-Jan Boele.
According to BlinkLab, the American Academy of Pediatrics advises that all children be screened for autism at 18 to 24 months. This is to refrain from delays in diagnosis, as many children miss critical windows for early intervention.
Dx1’s goal is to address these delays by helping healthcare providers deliver faster and more reliable assessments. The smartphone-based platform uses artificial intelligence to measure sensory sensitivity.
“After extensive app and portal development, stimulus refinement, and testing in hundreds of children, we are very confident in our (Food and Drug Administration) study's potential," Boele added.
Results from the targeted 100 participant study are scheduled for release in the third quarter of 2025. The trial will proceed to the main study thereafter, which aims to test 750 to 900 children.
BlinkLab’s submission for FDA 510(k) clearance is anticipated in 2026.
In 2023, privately held EarliTec Diagnostics came up with a similar innovation for autism detection. The company's creation focuses more on social-visual engagement, evaluating a child’s looking behaviour.
Currently, BlinkLab is the only ASX-listed company focusing on providing autism detection services or applications.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: BlinkLab is a client of the Investing News Network. This article is not paid-for content.
Keep reading...Show less
25 February
HeraMED Signs Strategic Collaboration Agreement with Garmin Health
HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.
- HeraMED has executed a collaboration agreement with Garmin;
- Agreement enables integration of Garmin smartwatch data through the Garmin Health API into HeraMED’s clinical grade remote monitoring pregnancy platform, HeraCARE;
- Expansion of the range of health data available to expectant mothers and their healthcare providers;
- HeraMED and Garmin will jointly collaborate on marketing efforts to promote their integrated solutions;
- Collaboration includes exploration of women's health research opportunities
Driven by Garmin Health, a leading provider of digital health solutions that leverage the data and insights of the Garmin product ecosystem, the collaboration will focus on data integration, joint marketing initiatives and exploration of women’s health research. Using the Garmin Health API, pregnant women who consent to sharing their health and fitness activity data through the Garmin Health API can wear Garmin smartwatches and have their health data collected and integrated into the HeraCARE platform, including:
- Expanded health metrics including heart rate, sleep patterns, and fitness activity levels
- Improved continuous monitoring capabilities for pregnant women
- Enhanced data quality and quantity for more informed decision-making
The collaboration will allow HeraCARE users to seamlessly connect their Garmin devices, providing a more comprehensive view of maternal health. This integration is expected to significantly augment the platform's existing capabilities, which include fetal and maternal heart rate monitoring, blood pressure tracking, and mood assessment. This collaboration will have an initial 3-year term with either group having the ability to withdraw by providing 3 months notice.
HeraMED Managing Director and CEO, Anoushka Gungadin, commented: “This is an incredibly exciting collaboration for HeraMED. Garmin is a globally recognised brand that has developed a specific smartwatch technology strategy for women. It is a significant step forward in our mission to revolutionise maternity care. By incorporating Garmin's high-quality sensor data into HeraCARE, we're expanding and enhancing our ability to provide continuous, real-time health insights to expectant mothers and their healthcare providers.
We are delighted to bring health and wellness data into our clinical grade platform for the purpose of transforming the model of care for maternity. The additional data points will contribute to HeraMED’s ‘data- as-an-asset’ approach with the possibility to monitor activities such as steps for pregnant mothers with hypertensive or diabetic conditions or sleep quality for our mental health care plans will only enrich the capability of HeraCARE.”
Garmin Health Senior Director of Global B2B Sales Joern Watzke said: “We are excited to collaborate with HeraMED to leverage Garmin smartwatch technology in support of women’s healthcare. This strategic relationship will highlight how Garmin wearable data can extend beyond informing daily healthy habits to supporting pregnancy monitoring by providing healthcare providers with valuable patient insights. By making smartwatch technology and advanced health data available for a variety of applications in the fields of healthcare, insurance and research, we believe Garmin is truly helping change the future of women’s healthcare for the better.”
In addition to the HeraCARE platform integration, HeraMED and Garmin will explore potential research collaborations and data integrations through the Garmin Health API focused on women’s health, including maternity care. This collaboration is dedicated to research and data rather than commercial and it is intended will develop specific research projects to be supported by targeted granting bodies in key target markets.
This collaboration agreement does not involve any direct financial consideration between the companies. However, HMD anticipates the collaboration is beneficial as it will enhance the HeraCARE platform by providing a more holistic view of maternal health by bringing health and wellness data together, and the additional data points will contribute to HMD's ‘data-as-an-asset’ strategy.
Click here for the full ASX Release
This article includes content from HeraMED Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
17 February
2 Biggest Medical Device ETFs in 2025
Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.
Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.
In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.
To help investors make decisions when it comes to medical device ETFs, here the Investing News Network provides a brief breakdown of what ETFs are and a look at the medical device ETFs you can invest in.
What is an exchange-traded fund?
Exchange-traded funds, or ETFs, hold a basket of equities, often focused on a theme or niche. ETFs are appealing because they give investors the ability to hone in on a specific market area without investing in individual companies. While they are similar to mutual funds, ETFs trade on stock exchanges in the same way stocks do.
Put simply, ETFs reduce the risk of investing by providing access to a larger pool of companies — they let investors pick an area that interests them and suffer less financially if one company under the ETF’s umbrella underperforms. In this way, ETFs allow investors to enter the market confidently and hopefully enjoy long-term capital gains.
Like many areas of the life science space, the medical device sector can be volatile, making ETFs particularly appealing. For example, if a company in a medical device ETF fails a clinical trial or receives negative feedback from the US Food and Drug Administration, ETF investors will largely be protected from any share price drop the stock might have.
On the other hand, if a company in a medical device ETF sees a major gain, that increase will also be muted for ETF investors. That's why some investors prefer to take their chances by adding individual stocks to their portfolios.
Medical device ETFs to consider
Investors keen on medical device ETFs only have three choices, according to ETFdb.com.
Here’s a brief look at the two biggest medical device ETFs available. The third ETF, the First Trust Indxx Medical Devices ETF (BATS:MDEV), is much smaller, with total assets of only US$2.16 million.
1. iShares US Medical Devices ETF (ARCA:IHI)
Total assets: US$5.1 billion
The iShares US Medical Devices ETF was launched in 2006 and tracked 50 holdings as of February 11, 2025. This iShares ETF has more than US$5.1 billion in assets under management and its top three constituents by weight are:
- Abbott Laboratories (NYSE:ABT): Abbott Laboratories’ medical devices are geared towards vascular disease, diabetes and vision care.
- Intuitive Surgical (NASDAQ:ISRG): This medical device firm is the maker of the da Vinci surgical and Ion endoluminal systems. These robotic products are designed to improve clinical outcomes for patients through minimally invasive surgery.
- Boston Scientific (NYSE:BSX): Boston Scientific's device portfolio is extensive. Its areas of focus include gastroenterology, cardiac and vascular surgery, neurological and orthopedic surgeries, and urology.
2. SPDR S&P Health Care Equipment ETF (ARCA:XHE)
Total assets: US$208.99 million
Formed on January 26, 2011, the SPDR S&P Health Care Equipment ETF tracked 66 holdings as of February 11, 2025. This SPDR ETF has more than US$208 million in assets under management and some of its top holdings are:
- Inari Medical (NASDAQ:NARI): Headquartered in California, Inari Medical developed the first mechanical thrombectomy system to receive FDA 510(k) clearance for the treatment of pulmonary embolism.
- AtriCure (NASDAQ:ATRC): Another venous-focused medical device company, AtriCure developed the first medical device to receive FDA approval for the treatment of persistent atrial fibrillation.
- iRhythm Technologies (NASDAQ:IRTC): Medical device firm iRhythym Technologies combines wearable biosensors and cloud-based data analytics with its proprietary algorithms to produce clinical actionable information.
This is an updated version of an article originally published by the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Keep reading...Show less
23 January
Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®
Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1
HCA Healthcare operates one of the most comprehensive hospital networks in the US, encompassing over 180 hospitals and approximately 2,400 sites of care in 20 states.
The national contract covering the deployment of Technegas in nuclear medicine departments across the entire HCA network was instigated by HCA after multiple of its sites entered into independent discussions with Cyclopharm regarding Technegas. This prompted HCA head office to initiate the creation of a broad-based contract which will bypass the need for individual site contract negotiations and most efficiently streamline the deployment of Technegas technology.
The agreement further underscores the commercial demand for Technegas which is already the preferred agent of choice in 65 countries outside the US for diagnosing lung conditions, including pulmonary embolism, hypertension, chronic obstructive pulmonary disease (COPD), and other respiratory diseases.
Cyclopharm CEO James McBrayer said, “We are thrilled to partner with HCA Healthcare, a leader in delivering quality care to millions of patients annually. This 3-year agreement will allow for the accelerated availability of Technegas across the US and reinforces our commitment to improving outcomes for patients with respiratory conditions.”
As well as streamlining implentation across up to 169 HCA nuclear medicine departments, today’s agreement opens discussions with the HealthTrust Purchasing Group (HealthTrust)2, HCA’s affiliated group purchasing organisation (GPO) that serves as the contracting and purchasing arm to a further network of over 1,800 hospitals in the USA.
Cyclopharm will now engage directly with individual HCA locations, clinical leaders and Divisional Directors to implement Technegas, prioritising those sites which had already entered preliminary discussions with Cyclopharm.
Technegas has been recognized globally for its ability to provide precise and reliable functional lung imaging. With this contract, HCA facilities will be at the forefront of adopting advanced nuclear medicine technology, ensuring better diagnostic and therapeutic options for their patients.
Mr. McBrayer concluded, “This agreement not only extends the footprint of Technegas in the US market but also sets the stage for its broader adoption within HealthTrust’s extensive network. We are proud to support HCA in its mission to provide exceptional care and are eager to see the positive impact of our technology on patients and clinicians alike.”
Click here for the full ASX Release
This article includes content from Cyclopharm Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
23 January
CONNEQT App Launches in USA as Pulse Deliveries Commence
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00